<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01383343</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2011-02595</org_study_id>
    <secondary_id>NCI-2011-02595</secondary_id>
    <secondary_id>CDR0000702751</secondary_id>
    <secondary_id>MC1017</secondary_id>
    <secondary_id>MC1017</secondary_id>
    <secondary_id>8877</secondary_id>
    <secondary_id>P30CA015083</secondary_id>
    <secondary_id>U01CA069912</secondary_id>
    <secondary_id>UM1CA186686</secondary_id>
    <nct_id>NCT01383343</nct_id>
  </id_info>
  <brief_title>Sorafenib Tosylate, Bevacizumab, Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer</brief_title>
  <official_title>Phase I Trial of FOLFIRI in Combination With Sorafenib and Bevacizumab in Patients With Advanced Gastrointestinal Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial studies the side effects and best dose of sorafenib tosylate when given
      together with bevacizumab, irinotecan hydrochloride, leucovorin calcium, and fluorouracil in
      treating patients with colorectal cancer that has spread to other parts of the body. Drugs
      used in chemotherapy, such as irinotecan hydrochloride, leucovorin calcium, and fluorouracil,
      work in different ways to stop the growth of tumor cells, either by killing the cells, by
      stopping them from dividing, or by stopping them from spreading. Sorafenib tosylate may stop
      the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal
      antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and
      spread. Sorafenib tosylate and bevacizumab may also block tumor growth in different ways by
      targeting certain cells. Giving sorafenib tosylate and bevacizumab together with combination
      chemotherapy may be a better treatment for colorectal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine the maximally tolerated dose of the combination of irinotecan hydrochloride,
      leucovorin calcium, and fluorouracil (FOLFIRI) plus sorafenib (sorafenib tosylate) plus
      bevacizumab.

      SECONDARY OBJECTIVES:

      I. To assess the safety of FOLFIRI plus sorafenib plus bevacizumab. II. To assess the
      feasibility of the proposed combination. III. To evaluate the response rate and identify any
      activity of the proposed combination.

      OUTLINE: This is a dose-escalation study of sorafenib tosylate followed by a cohort study.
      (Cohort study cancelled as of March 25, 2014)

      Patients receive irinotecan hydrochloride intravenously (IV) over 90 minutes on day 1,
      leucovorin calcium IV over 2 hours on day 1, fluorouracil IV continuously over 46 hours on
      days 1-2, bevacizumab IV over 30-90 minutes on day 1, and sorafenib tosylate orally (PO) once
      (QD) or twice daily (BID) on days 3-6 and 10-13*. Courses repeat every 14 days in the absence
      of disease progression or unacceptable toxicity.

      NOTE: *Patients may also receive sorafenib tosylate on days 7 and 14.

      After completion of study therapy, patients are followed up for 3 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">February 2017</completion_date>
  <primary_completion_date type="Actual">February 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of sorafenib tosylate in combination with FOLFIRI and bevacizumab, defined as the dose level below the lowest dose that induces dose-limiting toxicity in at least one-third of patients (at least 2 of a maximum of 6 new patients)</measure>
    <time_frame>14 days</time_frame>
    <description>Graded using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events of sorafenib tosylate in combination with bevacizumab and FOLFIRI as assessed by NCI CTCAE v 4.0</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>The number and severity of all adverse events (overall, by dose-level, and by tumor group) will be tabulated and summarized in this patient population. The grade 3+ adverse events will also be described and summarized in a similar fashion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate in patients treated with sorafenib tosylate in combination with FOLFIRI and bevacizumab, assessed using Response Evaluation Criteria in Solid Tumors</measure>
    <time_frame>From the start of the treatment until disease progression/recurrence, assessed up to 3 months</time_frame>
    <description>Responses will be summarized by simple descriptive summary statistics delineating complete and partial responses as well as stable and progressive disease in this patient population (overall and by tumor group).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>Up to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure</measure>
    <time_frame>Time from registration to documentation of progression, unacceptable toxicity, or refusal to continue participation by the patient, assessed up to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to until treatment related grade 3+ toxicity assessed via CTC standard toxicity grading</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Will be assessed using continuous variables as the outcome measures (primarily nadir). Overall toxicity incidence as well as toxicity profiles by dose level, patient and tumor site will be explored and summarized. Frequency distributions, graphical techniques and other descriptive measures will form the basis of these analyses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time until any treatment related toxicity evaluated via the ordinal Common Toxicity Criteria (CTC) standard toxicity grading</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Overall toxicity incidence as well as toxicity profiles by dose level, patient and tumor site will be explored and summarized. Frequency distributions, graphical techniques and other descriptive measures will form the basis of these analyses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time until hematologic nadirs (ANC, platelets, hemoglobin)</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Descriptive statistics and simple scatter plots will form the basis of presentation of these data.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Recurrent Colon Carcinoma</condition>
  <condition>Recurrent Rectal Carcinoma</condition>
  <condition>Stage IVA Colon Cancer</condition>
  <condition>Stage IVA Rectal Cancer</condition>
  <condition>Stage IVB Colon Cancer</condition>
  <condition>Stage IVB Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (FOLFIRI and bevacizumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive irinotecan hydrochloride IV over 90 minutes on day 1, leucovorin calcium IV over 2 hours on day 1, fluorouracil IV continuously over 46 hours on days 1-2, bevacizumab IV over 30-90 minutes on day 1, and sorafenib tosylate PO QD or BID on days 3-6 and 10-13*. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (FOLFIRI and bevacizumab)</arm_group_label>
    <other_name>Anti-VEGF</other_name>
    <other_name>Anti-VEGF Humanized Monoclonal Antibody</other_name>
    <other_name>Anti-VEGF rhuMAb</other_name>
    <other_name>Avastin</other_name>
    <other_name>Bevacizumab Biosimilar BEVZ92</other_name>
    <other_name>Bevacizumab Biosimilar BI 695502</other_name>
    <other_name>Bevacizumab Biosimilar FKB238</other_name>
    <other_name>Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer</other_name>
    <other_name>Recombinant Humanized Anti-VEGF Monoclonal Antibody</other_name>
    <other_name>rhuMab-VEGF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorouracil</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (FOLFIRI and bevacizumab)</arm_group_label>
    <other_name>5-Fluoro-2,4(1H, 3H)-pyrimidinedione</other_name>
    <other_name>5-Fluorouracil</other_name>
    <other_name>5-Fluracil</other_name>
    <other_name>5-FU</other_name>
    <other_name>AccuSite</other_name>
    <other_name>Carac</other_name>
    <other_name>Fluoro Uracil</other_name>
    <other_name>Fluouracil</other_name>
    <other_name>Flurablastin</other_name>
    <other_name>Fluracedyl</other_name>
    <other_name>Fluracil</other_name>
    <other_name>Fluril</other_name>
    <other_name>Fluroblastin</other_name>
    <other_name>Ribofluor</other_name>
    <other_name>Ro 2-9757</other_name>
    <other_name>Ro-2-9757</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (FOLFIRI and bevacizumab)</arm_group_label>
    <other_name>Campto</other_name>
    <other_name>Camptosar</other_name>
    <other_name>Camptothecin 11</other_name>
    <other_name>Camptothecin-11</other_name>
    <other_name>CPT 11</other_name>
    <other_name>CPT-11</other_name>
    <other_name>Irinomedac</other_name>
    <other_name>U-101440E</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin Calcium</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (FOLFIRI and bevacizumab)</arm_group_label>
    <other_name>Adinepar</other_name>
    <other_name>Calcifolin</other_name>
    <other_name>Calcium (6S)-Folinate</other_name>
    <other_name>Calcium Folinate</other_name>
    <other_name>Calcium Leucovorin</other_name>
    <other_name>Calfolex</other_name>
    <other_name>Calinat</other_name>
    <other_name>Cehafolin</other_name>
    <other_name>Citofolin</other_name>
    <other_name>Citrec</other_name>
    <other_name>Citrovorum Factor</other_name>
    <other_name>Cromatonbic Folinico</other_name>
    <other_name>Dalisol</other_name>
    <other_name>Disintox</other_name>
    <other_name>Divical</other_name>
    <other_name>Ecofol</other_name>
    <other_name>Emovis</other_name>
    <other_name>Factor, Citrovorum</other_name>
    <other_name>Flynoken A</other_name>
    <other_name>Folaren</other_name>
    <other_name>Folaxin</other_name>
    <other_name>FOLI-cell</other_name>
    <other_name>Foliben</other_name>
    <other_name>Folidan</other_name>
    <other_name>Folidar</other_name>
    <other_name>Folinac</other_name>
    <other_name>Folinate Calcium</other_name>
    <other_name>folinic acid</other_name>
    <other_name>Folinic Acid Calcium Salt Pentahydrate</other_name>
    <other_name>Folinoral</other_name>
    <other_name>Folinvit</other_name>
    <other_name>Foliplus</other_name>
    <other_name>Folix</other_name>
    <other_name>Imo</other_name>
    <other_name>Lederfolat</other_name>
    <other_name>Lederfolin</other_name>
    <other_name>Leucosar</other_name>
    <other_name>leucovorin</other_name>
    <other_name>Rescufolin</other_name>
    <other_name>Rescuvolin</other_name>
    <other_name>Tonofolin</other_name>
    <other_name>Wellcovorin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib Tosylate</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (FOLFIRI and bevacizumab)</arm_group_label>
    <other_name>BAY 43-9006 Tosylate</other_name>
    <other_name>BAY 54-9085</other_name>
    <other_name>Nexavar</other_name>
    <other_name>sorafenib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  This trial is intended for gastrointestinal malignancies appropriate for
             irinotecan-based therapy; histologic proof of cancer that is now unresectable; if
             prior therapy was received, patients must have shown progressive disease during prior
             treatment or within 6 months of their most recent therapy

          -  Measurable disease or non-measurable disease

          -  Absolute neutrophil count (ANC) &gt;= 1500/uL

          -  Platelet (PLT) &gt;= 100,000/uL

          -  Hemoglobin (Hgb) &gt;= 9.0 gm/dL

          -  Total bilirubin =&lt; upper limit of normal (ULN)

          -  Alkaline phosphatase =&lt; 3 x ULN

          -  Aspartate aminotransferase (AST) =&lt; 3 x ULN OR AST =&lt; 5 x ULN if liver involvement

          -  International normalized ratio (INR) &lt; 1.5 unless patients are receiving
             anti-coagulation therapy; patients receiving anti-coagulation therapy with an agent
             such as warfarin or heparin are allowed to participate if INR =&lt; 3.0

          -  Urine protein creatinine (UPC) ratio &lt; 1 or urine dipstick &lt; 2+

               -  NOTE: urine protein must be screened by urine analysis for UPC ratio or by
                  dipstick; for UPC ratio &gt;= 1.0, 24-hour urine protein must be obtained and the
                  level should be &lt; 1000 mg

          -  Creatinine =&lt; 1.5 x ULN

          -  Calculated creatinine clearance must be &gt;= 45 mL/min using the Cockcroft-Gault formula

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1

          -  Ability to provide informed consent

          -  Willing to return to Mayo Clinic for follow up

          -  Life expectancy &gt;= 84 days (3 months)

          -  Women of childbearing potential only: negative pregnancy test done =&lt; 7 days prior to
             registration

        Exclusion Criteria:

          -  Known standard therapy for patient's disease that is potentially curative

        Note:

          -  Prior treatment with irinotecan, 5-fluoruracil or bevacizumab is allowed

          -  Prior treatment with sorafenib is not allowed

               -  Inadequately controlled hypertension (systolic blood pressure of &gt; 150 mmHg or
                  diastolic pressure &gt; 100 mmHg on anti-hypertensive medications)

               -  Prior history of hypertensive crisis or hypertensive encephalopathy

               -  History of myocardial infarction or unstable angina =&lt; 6 months prior to
                  registration or congestive heart failure requiring use of ongoing maintenance
                  therapy for life-threatening ventricular arrhythmias

               -  Heart failure New York Heart Association classification III or IV

               -  Thrombolic or embolic events such as a cerebrovascular accident including
                  transient ischemic attacks =&lt; 6 months prior to registration

               -  Any hemorrhage/bleeding event &gt; grade 3 =&lt; 4 weeks prior to registration

               -  Evidence or history of bleeding diathesis (greater than normal risk of bleeding)
                  or coagulopathy (in the absence of therapeutic anticoagulation); NOTE: patients
                  on full-dose anticoagulants are eligible provided the patient has been on a
                  stable dose for at least 2 weeks of low molecular weight heparin or warfarin and
                  has an INR in the range of 2-3; aspirin doses &gt; 325 mg PO daily are not allowed

               -  Active or recent hemoptysis (&gt;= Â½ teaspoon of bright red blood per episode) =&lt; 30
                  days prior to registration

               -  Serious, non-healing wound, active ulcer, or untreated bone fracture; NOTE:
                  patients with fractures secondary to metastatic disease are eligible after
                  appropriate radiotherapy

               -  Significant vascular disease (e.g., aortic aneurysm, aortic dissection), recent
                  peripheral arterial thrombosis, symptomatic peripheral vascular disease =&lt; 6
                  months prior to registration

               -  History of abdominal fistula, gastrointestinal perforation, or intra-abdominal
                  abscess =&lt; 6 months prior to registration

               -  Major surgical procedures, open biopsy, or significant traumatic injury =&lt; 28
                  days prior to registration or anticipation of need for major surgical procedure
                  during the course of the study; EXCEPTION: core biopsy or minor surgical
                  procedure, including placement of a vascular access device, =&lt; 7 days prior to
                  registration is allowed

               -  Patients taking cytochrome P450 enzyme-inducing antiepileptic drugs =&lt; 4 weeks
                  prior to registration will be excluded (phenytoin, carbamazepine, phenobarbital,
                  rifampin, or St. John's wort)

               -  Known or suspected allergy or hypersensitivity to any agent given in the course
                  of this trial

               -  Any condition that impairs patient's ability to swallow whole pills

               -  Any malabsorption problem

               -  Any of the following prior therapies:

          -  Chemotherapy =&lt; 14 days prior to registration

          -  Immunotherapy =&lt; 28 days prior to registration

          -  Radiation therapy =&lt; 28 days prior to registration

          -  Radiation to &gt; 25% of bone marrow

               -  Failure to fully recover from acute, reversible effects of prior chemotherapy
                  regardless of interval since last treatment

               -  Known brain metastasis; NOTE: patients with neurological symptoms must undergo a
                  computed tomography (CT) scan/magnetic resonance imaging (MRI) of the brain to
                  exclude brain metastasis

               -  Any of the following:

          -  Pregnant women

          -  Nursing women

          -  Men or women of childbearing potential who are unwilling to employ adequate
             contraception

               -  Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary
                  therapy considered investigational (utilized for a non-Food and Drug
                  Administration [FDA]-approved indication and in the context of a research
                  investigation)

               -  Receiving any other investigational agent which would be considered as a
                  treatment for the primary neoplasm

               -  Co-morbid systemic illnesses or other severe concurrent disease which, in the
                  judgment of the investigator, would make the patient inappropriate for entry into
                  this study or interfere significantly with the proper assessment of safety and
                  toxicity of the prescribed regimens

               -  Other active malignancy =&lt; 3 years prior to registration; EXCEPTIONS:
                  non-melanotic skin cancer or carcinoma-in-situ of the cervix; NOTE: if there is a
                  history of prior malignancy, they must not be receiving other specific treatment
                  for their cancer, including hormonal therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joleen Hubbard</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic in Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224-9980</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2011</study_first_submitted>
  <study_first_submitted_qc>June 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2011</study_first_posted>
  <last_update_submitted>April 18, 2017</last_update_submitted>
  <last_update_submitted_qc>April 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Rectal Neoplasms</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Endothelial Growth Factors</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Immunoglobulin G</mesh_term>
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

